The orders were for Microbix QAPs, in both the traditional liquid-vials and formatted onto Copan® FLOQSwabs®, to support proficiency programs covering numerous infectious diseases across multiple disease categories. The QAPs provided included those to support antigen and molecular (i.e., PCR) tests. They will be used to help validate accuracy of testing on a wide range of test systems – ranging from high-throughput automated instruments to lower volume point-of-care and lab-developed tests.
These sales were realized in the fourth quarter of calendar 2023 (i.e., Q1 of Microbix’s fiscal 2024). As with the over
Microbix believes this record set of orders substantiates its technical leadership in creating and producing test controls (i.e., QAPs). Specifically, that the accuracy and reliability of sophisticated clinical laboratory testing must be validated by PT/EQA programs and that such programs must be supported by cross-platform compatible QAPs in formats that represent actual patient samples (i.e., both liquids & swabs).
About
Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, most notably viral transport medium (DxTM™) to stabilize patient samples for lab-based molecular diagnostic testing and Kinlytic® urokinase, a biologic thrombolytic drug used to treat blood clots. Microbix is traded on the TSX and OTCQX, and headquartered in
Forward-Looking Information
This news release includes “forward-looking information,” as such term is defined in applicable securities laws. Forward-looking information includes, without limitation, discussion of the PT/EQA customer purchases of QAPs and their relevance, Microbix’s business and business results, goals or outlook, risks associated with financial results and stability, development projects such as those referenced in its corporate presentation, regulatory compliance and approvals, sales to foreign jurisdictions, engineering and construction, production (including control over costs, quality, quantity and timeliness of delivery), foreign currency and exchange rates, maintaining adequate working capital and raising further capital on acceptable terms or at all, and other similar statements concerning anticipated future events, conditions or results that are not historical facts. These statements reflect management’s current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward-looking information is inherently uncertain, and that actual performance may be affected by many material factors, some of which are beyond the Company’s control. Accordingly, actual future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. All statements are made as of the date of this news release and represent the Company’s judgement as of the date of this new release, and the Company is under no obligation to update or alter any forward-looking information.
Please visit www.microbix.com or www.sedarplus.ca for recent Microbix news and filings.
For further information, please contact Microbix at:
CEO (905) 361-8910 | CFO (905) 361-8910 | Investor Relations (647) 203-8793 ir@microbix.com |
Copyright © 2024 Microbix Biosystems Inc.
Microbix®, DxTM™, Kinlytic®, ONBOARDx™, and QAPs™ are trademarks of
Copan®, FLOQ®, and FLOQSwab® are trademarks of
Source:
2024 GlobeNewswire, Inc., source